

Activation of adaptive and innate immune cells via localized Interleukin-2 cytokine factories eradicates mesothelioma tumors

Amanda M. Nash^{1,*}, Samira Aghlara-Fotovat^{1,*}, Bertha Castillo¹, Andrea Hernandez¹, Aarthi Pugazenthi², Hyun-Sung Lee², Hee-Jin Jang², Annie Nguyen¹, Alexander Lu¹, Bryan M. Burt², Ravi K. Ghanta², and Omid Veisheh^{1,#}

¹Department of Bioengineering, Rice University, Houston, TX,

²Michael E. DeBakey Department of Surgery, Baylor College of Medicine, Houston, TX

*These authors contributed equally

For Correspondence: Omid Veisheh, 6500 Main St. Houston, Tx 77030, Tel.: +1 713 348 3082, email: omid.veisheh@rice.edu

Contents

Supplemental Table 1. Mouse antibody panels for CyTOF (cytokines)..... 3

Supplemental Figure 1. Dose dependent anti-tumor effects of RPE-mIL2 administration..... 5

Supplemental Figure 2. CD8+ T cells are needed for a robust anti-tumor response in mice with MPM tumors 6

Supplemental Figure 3. Combination treatment did not cause significant deviations in body weight. 7

Supplemental Figure 4. aPD-1 therapy is not effective as a single agent for MPM tumors..... 8

Supplemental Figure 5. Combination of RPE-mIL2 and aPD1 checkpoint therapy elicit MPM tumor eradication..... 9

Supplemental Figure 6. Gating strategies of CyTOF data. 10

Supplemental Figure 7. RPE-hIL2 Pharmacokinetics in immunocompetent mice. 11

Supplemental Figure 8. Toxicological analysis of RPE-hIL2 in the rat pleura..... 12

Supplemental Figure 9. Safe and local delivery of capsules to the pleural space via catheter..... 12

Supplemental Table 1. Mouse antibody panels for CyTOF (cytokines).

Label	Cytokine			
	Target	clone	Source	Cat. No
89Y	CD45(Ms)	30-F11	DVS-Fluidigm	3089005B
111Cd	CD44	IM7	Tonbo	70-0441-U100
115In	CD4(Ms)	RM4-5	BioLegend	100506
127IdU	S-phase cell cycle			
139La	CD11b	M1/70	BioLegend	101249
141Pr	Ly-6G	1A8	DVS-Fluidigm	3141008B
142Nd	CD11c	Polyclonal	DVS-Fluidigm	3142003B
143Nd	IL-5	TRFK5	DVS-Fluidigm	3143003B
144Nd	IL-2	JES6-5H4	DVS-Fluidigm	3144002B
145Nd	CD69	H1.2F3	DVS-Fluidigm	3145005B
146Nd	CD8a (Ms)	53-6.7	DVS-Fluidigm	3146003B
147Sm	CD103	2.00E+07	BioLegend	121401
148Nd	CD27	LG.3A10	BioLegend	124202
149Sm	CD19 (Ms)	6D5	DVS-Fluidigm	3149002B
150Nd	CD25	3C7	BioLegend	101902
151Eu	CD64	X54-5/7.1	DVS-Fluidigm	3151012B
152Sm	CD3e	145-2C11	DVS-Fluidigm	3152004B
153Eu	CD274, PD-L1	10F.9G2	DVS-Fluidigm	3153016B
154Sm	IFNa	RMMA-1	PBL	22100-1
155Gd	CCR7	4B12	eBioscience	16-1971-85
156Gd	TCR beta	H57-597	BioLegend	109201
158Gd	IL-10(Ms)	JES5-16E3	DVS-Fluidigm	3158002B
159Tb	IL-12	C15.6	BD	554477
160Gd	CD62L	MEL-14	DVS-Fluidigm	3160008B
161Dy	CD40	HM40-3	DVS-Fluidigm	3161020B
162Dy	TNFa	MP6-XT22	DVS-Fluidigm	3162002B
163Dy	CD152, CTLA-4	9H10	BioLegend	106202
164Dy	LAP, TCF-beta	TW7-16B4	DVS-Fluidigm	3164014B
165Ho	IFNg	XMG1.2	DVS-Fluidigm	3165003B
166Er	IL-4	11B11	DVS-Fluidigm	3166003B
167Er	IL-6	MP5-20F3	DVS-Fluidigm	3167003B
168Er	Ki67	B56	BD	556003
169Tm	CD127	A7R34	Tonbo	70-1271-U100
170Er	NK1.1	PK136	DVS-Fluidigm	3170002B
171Yb	PD-1	29F.1A12	BioLegend	135202
172Yb	CD86	GL1	DVS-Fluidigm	3172016B
173Yb	F4/80	BM8	BioLegend	123102
174Yb	CD326 (Ms)	G8.8	BioLegend	118201
175Lu	CD317	927	BioLegend	127002

176Yb	B220, CD45R	RA3-6B2	BioLegend	103202
191Ir	Ir DNA-intercalator			
198Pt	Cell viability			
209Bi	I-A/I-E, MHC-II	M5/114.15.2	DVS-Fluidigm	3209006B